Sorafenib Inhibits Interferon Production by Plasmacytoid Dendritic Cells in Hepatocellular Carcinoma
Overview
Affiliations
Background: Sorafenib is a multi-kinase inhibitor that shows antitumor activity in advanced hepatocellular carcinoma. Sorafenib exerts a regulatory effect on immune cells, including T cells, natural killer cells and dendritic cells. Studies have shown that plasmacytoid dendritic cells (pDCs) are functionally impaired in cancer tissues or produce low type I interferon alpha (IFNα) in cancer microenvironments. However, the effects of sorafenib on the function of pDCs have not been evaluated in detail.
Methods: Normal and patient PBMCs were stimulated with CpG-A to evaluate IFNα production with Flow cytometry and ELISA.
Result: We analyzed the production of IFNα by PBMCs in patients with advanced HCC under sorafenib treatment. We found that sorafenib-treated HCC patients produced less IFNα than untreated patients. Furthermore, we demonstrated that sorafenib suppressed the production of IFNα by PBMCs or pDCs from heathy donors in a concentration-dependent manner.
Conclusion: Sorafenib suppressed pDCs function. Given that sorafenib is a currently recommended targeted therapeutic agent against cancer, our results suggest that its immunosuppressive effect on pDCs should be considered during treatment.
Hansen F, David P, Weber G Cancers (Basel). 2024; 16(12).
PMID: 38927922 PMC: 11201847. DOI: 10.3390/cancers16122216.
Xie Y, Wu H, He Y, Liu L, Huang I, Zhou L Cell Death Dis. 2024; 15(2):110.
PMID: 38310091 PMC: 10838288. DOI: 10.1038/s41419-024-06493-0.